MIRXES-B (02629) surged nearly 9%, reaching a high of HK$40.66 to set a new listing record, representing over 70% gain from its IPO price of HK$23.3. As of press time, the stock was up 8.96% at HK$40.62, with turnover of HK$16.66 million.

According to public information, Mirxes is a Singapore-headquartered RNA biotechnology company dedicated to developing and commercializing precise, non-invasive, and affordable blood miRNA testing for early screening of cancer and other diseases. The company's flagship product GASTROClear™ is a blood miRNA-based molecular diagnostic kit for gastric cancer screening that has been approved in multiple countries including Singapore and the European Union, and has received FDA Breakthrough Device Designation in the United States.

GASTROClear™ has completed a prospective clinical trial involving 9,472 participants in China and is currently under regulatory review for approval.

Guoyuan International believes that the company has significant technological, product, and market advantages in miRNA-based early cancer detection, positioning it as one of the global leaders in this field. Everbright Securities International previously noted that the global cancer screening market offers vast opportunities with high industry barriers to entry. GASTROClear™ is the only approved molecular diagnostic IVD product for gastric cancer screening in the global market and holds the largest market share (66.3%) in Southeast Asia's miRNA-based liquid biopsy gastric cancer screening market based on 2023 revenue.